1735-89-3

Basic information

• Product Name: 6-TRIFLUOROMETHYLOXINDOLE
• Synonyms: 6-TRIFLUOROMETHYLOXINDOLE;BUTTPARK 24\07-32;6-(Trifluoromethyl)-2-oxoindole;6-(Trifluoromethyl)oxindole 97%;6-(Trifluoromethyl)oxindole97%;6-(TRIFLUOROMETHYL)OXINDOLE ,98%;6-TRIFLUOROMETHYLOXINDOLE 97.0%;6-TRIFLUROMETHYL-2-OXINDOLE
• CAS NO: 1735-89-3
• Molecular Formula: C₉H₆F₃NO
• Molecular Weight: 201.15
• EINECS: 1312995-182-4
• Product Categories: blocks;FluoroCompounds;IndolesOxindoles;Indole/indoline/oxindole;Indoline & Oxindole;Indoles;Boronic Acid;Heterocyclic Compounds
• Mol File: 1735-89-3.mol

Chemical Properties

• Melting Point: 184-186
• Boiling Point: 289.8 ºC at 760 mmHg
• Flash Point: 129.1 ºC
• Appearance: /
• Density: 1.391 g/cm³
• Vapor Pressure: 0.00215mmHg at 25°C
• Refractive Index: 1.496
• Storage Temp.: Keep Cold
• PKA: 13.34±0.20(Predicted)
• CAS DataBase Reference: 6-TRIFLUOROMETHYLOXINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-TRIFLUOROMETHYLOXINDOLE(1735-89-3)
• EPA Substance Registry System: 6-TRIFLUOROMETHYLOXINDOLE(1735-89-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-43
• Safety Statements: 36/37-24/25
• Hazardous Substances Data: 1735-89-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-TRIFLUOROMETHYLOXINDOLE is used as a key intermediate in the synthesis of oxindole derivatives, which are known for their potential as neuronal death inhibitors. These derivatives have therapeutic applications in the treatment of neurodegenerative diseases, where they can help protect neurons from damage and death, thereby slowing down disease progression.
In the preparation of these oxindole derivatives, 6-TRIFLUOROMETHYLOXINDOLE serves as a building block that can be further modified and functionalized to develop new drugs with improved efficacy and selectivity. Its unique trifluoromethyl group also contributes to the overall pharmacokinetic properties of the resulting compounds, potentially enhancing their stability, bioavailability, and target engagement.
Overall, 6-TRIFLUOROMETHYLOXINDOLE plays a crucial role in the development of novel therapeutic agents for the treatment of neurodegenerative disorders, offering a promising avenue for research and drug discovery in the pharmaceutical industry.

InChI:InChI=1/C9H6F3NO/c10-9(11,12)6-2-1-5-3-8(14)13-7(5)4-6/h1-2,4H,3H2,(H,13,14)

Upstream product

• 13544-07-5 methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate 
• 1735-91-7 2-(2-nitro-4-(trifluoromethyl)phenyl)acetic acid 
• 13088-15-8 diethyl 2-(2-nitro-4-(trifluoromethyl)phenyl)malonate 
• 65754-26-9 2-methyl-5-trifluoromethylnitrobenzene 
• 290825-52-4 dimethyl 2-(2-nitro-4-trifluoromethylphenyl)malonate 

Downstream Products

• 865079-95-4 3-[1-Phenyl-meth-(E)-ylidene]-6-trifluoromethyl-1,3-dihydro-indol-2-one 
• 865080-02-0 (2'R,3'S,4'R,5'R)-1'-((1R,2S)-2-Hydroxy-1,2-diphenyl-ethyl)-2'-isobutyl-2-oxo-4'-phenyl-6-trifluoromethyl-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid dimethylamide 
• 73425-84-0 Methyl-(7-trifluoromethyl-2,3,4,9-tetrahydro-thiopyrano[2,3-b]indol-4-ylmethyl)-amine; hydrochloride 
• 950202-40-1 1-(3,5-dimethyl-phenyl)-6-trifluoromethyl-1,3-dihydro-indol-2-one 

Relevant articles and documents

A safe and selective method for reduction of 2-nitrophenylacetic acid systems to N-aryl hydroxamic acids using continuous flow hydrogenation

The cyclic hydroxamic acid functional group is critical to the biological activity of numerous natural products and drug candidates. Efficient, reliable, and green synthetic methods to produce cyclic hydroxamic acids are needed. Herein, flow hydrogenation has been explored as a novel approach toward achieving the selective partial reduction of 2-nitrophenylacetic acid to 1-hydroxyindolin-2-one. The bidentate ligand, 1,10-phenanthroline, has been identified as a unique inhibitor for modulating product selectivity in this Pt/C-catalyzed process. Under the newly optimized reaction conditions, the targeted hydroxamic acid is produced with high selectivity (49:1) over the lactam by-product. The scope of the reaction is demonstrated for a variety of 2-nitrophenylacetic acid derivatives.

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors

A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel, selective compounds, that inhibit JNK3, but not p38 MAP kinase and provided key insights into understanding the behavior of gatekeeper residue methionine-146 in determining target selectivity for this series.

SYNTHESIS OF THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS

Disclosed herein are various methods for synthesizing compounds that modulate thrombopoietin activity. Also disclosed are intermediates useful for the preparation of these compounds.

3-heteroarylidene-2-indolinone protein kinase inhibitors

The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors

The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

Oxindole derivatives

The invention relates to compounds of formula (I), wherein: R2represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C2-4alkanoyl, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylthio, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, {overscore (N)}—C1-4alkylcarbamoyl, {overscore (N)},{overscore (N)}-di(C1-4alkyl)carbamoyl, aminosulphonyl, {overscore (N)}—C1-4alkylaminosulphonyl, {overscore (N)},{overscore (N)}-di(C1-4alkyl)aminosulphonyl, C1-4alkylsulphonylamino, or a group R4X1wherein X1represents a direct bond, C2-4alkanoyl, —CONR5R6—, —SO2NR7R8— or —SO2R9— (wherein R5and R7, each independently represents hydrogen or C1-2alkyl and R6, R8and R9each independently represents C1-4alkyl and wherein R4is linked to R6, R8or R9) and R4represents an optionally substituted group selected from phenyl and a 5 or 6-membered heterocyclic group; n is an integer from 0 to 4, R1represents hydrogen, C1-4alkyl, C1-4alkoxymethyl, di(C1-4alkoxy)methyl or C1-4alkanoyl; m is an integer from 0 to 4; and R3represents hydroxy, halogeno, nitro, trifluoromethyl, C1-3alkyl, cyano, amino or R10X2(wherein X2represents a direct bond, —CH2—, or a single or double heteroatom linker group including —S—, —SO— and —NR15— (wherein R15represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl), and R10is an alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or R10is an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF and FGF, properties of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors

The present invention relates to novel 3-(cycloalkanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.